Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 6.8% – What’s Next?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) shares rose 6.8% during trading on Wednesday. The stock traded as high as $16.50 and last traded at $16.3910. 12,451 shares changed hands during trading, an increase of 84% from the average daily volume of 6,777 shares. The stock had previously closed at $15.35.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on AAPG. BTIG Research reiterated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a research report on Friday, August 21st. B. Riley Financial initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price target on the stock. Finally, Raymond James Financial restated a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. Two investment analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $46.43.

Ascentage Pharma Group International Stock Up 6.8%

The firm’s 50-day moving average price is $17.21 and its 200 day moving average price is $19.76. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. As a group, research analysts expect that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current year.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.